<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617746</url>
  </required_header>
  <id_info>
    <org_study_id>AR012</org_study_id>
    <nct_id>NCT01617746</nct_id>
  </id_info>
  <brief_title>Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma</brief_title>
  <official_title>Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to determine if blockade of endothelin 1 signalling via
      endothelin receptor A using ambrisentan or dual blockade (A&amp;B) via bosentan can provide
      protection against methacholine induced bronchoconstriction in asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelin 1 may have a role in the development of acute airway narrowing in asthma. Blockade
      of the endothelin system may thereby protect against airway narrowing. Two receptors exist
      for endothelin 1, Endothelin A &amp; B. Both can be blocked by Bosentan, and the A receptor by
      ambrisentan. Both medications are currently in use for the treatment of pulmonary arterial
      hypertension. The investigators will endeavour to examine the potential role of endothelin 1
      in the development of airway narrowing in asthma through blockade of the endothelin receptors
      A&amp;B through the use of bosentan and ambrisentan.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in doubling dose of methacholine to produce bronchoconstriction compared to placebo</measure>
    <time_frame>2 weeks</time_frame>
    <description>Both active treatments will be compared against placebo with respect to protection against methacholine induced bronchoconstriction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Which of the endothelin receptors A&amp;B are most bronchoprotective against methacholine</measure>
    <time_frame>2 weeks</time_frame>
    <description>Both bostentan and ambrisentans effect on airway response to methacholine will be compared to placebo. The relative efficacy will be compared, in terms of doubling doses of methacholine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Ambrisentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg od ambrisentan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>62.5mg bosentan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan</intervention_name>
    <description>5mg od two weeks</description>
    <arm_group_label>Ambrisentan</arm_group_label>
    <other_name>Volibris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>62.5mg bd two weeks</description>
    <arm_group_label>Bosentan</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>bd for two weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Physician diagnosis of asthma confirmed objectively by airway hyperactivity to
             methacholine (as determined by a ≥ 20% drop in FEV at a methacholine dose of ≤ 8mg/ml
             after β-agonist withdrawal as per ATS guidelines)

          2. Age range 18-60 years

          3. FEV1 ≥ 60% predicted

          4. Duration of asthma &gt; 6 months and on stable medication for 4 weeks

          5. Prescribed and compliant with inhaled corticosteroid up to a maximum of 2000mcg
             beclomethasone or equivalent

          6. No history of previous regular smoking and current non-smoker

        Exclusion Criteria:

          1. Unstable asthma; defined as the presence of 1 or more of the following events in the
             month prior to study [Emergency/'out of hours' visit to GP for asthma exacerbation; GP
             visit to patient at home for asthma exacerbation or A &amp; E/hospital admission for
             asthma exacerbation]

          2. Treatment with oral corticosteroids in the past month

          3. Need for maintenance oral corticosteroid therapy

          4. Pregnancy or planning to become pregnant over course of study and up to one month
             after

          5. Excessive risk of hepatotoxicity from endothelin receptor antagonists;

               -  Alcohol excess (defined as regular consumption above government daily recommend
                  limits; currently defined as 28 units per wk for men, 21 units per week for
                  women)

               -  Previous intravenous drug use

               -  Current or known history of liver disease (with the exception of Gilberts disease
                  and gallstones)

               -  Chronic hepatitis (either viral (e.g. hepatitis B or C) or autoimmune)

               -  Bilirubin, alanine aminotransferase (ALT) or asparate aminotransferase (AST)
                  greater than the upper limit of normal at screening

          6. Anaemia (defined as haemoglobin below the lower reference range for sex) at screening

          7. Renal failure (defined as eGFR less than 50 mL/minute/1.73 m2) at screening

          8. Known HIV positivity

          9. History of inability to tolerate bosentan or ambrisentan

         10. Significant medical conditions other than asthma felt by investigator to preclude
             participation in study. This could be either in patients best interest or due to
             potential to significantly alter responses to medication and hence alter power of
             clinical trial (examples include; significant heart failure (NYHA grades II-IV),
             diabetes mellitus, bronchiectasis or haematological malignancy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Spears, MBChB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Spears, MBChB PhD</last_name>
    <phone>0141 211 1673</phone>
    <email>mark.spears@glasgow.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rekha Chaudhuri, MD</last_name>
    <phone>0141 211 1673</phone>
    <email>rekhachaudhuri@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asthma Research Unit, University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Spears, MD PhD</last_name>
      <phone>441412111673</phone>
      <email>mark.spears@glasgow.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rekha Chaudhuri, MD</last_name>
      <phone>441412111673</phone>
      <email>rekhachaudhuri@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Spears, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rekha Chaudhuri</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neil C Thomson, MD FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>June 10, 2012</last_update_submitted>
  <last_update_submitted_qc>June 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Mark Spears</investigator_full_name>
    <investigator_title>Clinical Lecturer</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Endothelin</keyword>
  <keyword>Airway hyperreactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

